Podcasts about Merck

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

On today's episode, Yaron Werber, John Maraganore, Sam Fazeli, and Matt Gline open with a discussion of biotech market volatility, with Matt noting that it often seems driven more by opaque factor dynamics than company-specific fundamentals. The group then turns to Eli Lilly's continued “Amazonification” and reinventing the pharma business as it acquires a variety of different companies, including this week's $2.8B upfront acquisition of Atai Beckley, a psychedelic-focused company. The conversation turns to BioCentury's reporting on Asia-to-West NewCos, prompting a debate about whether China is uniquely changing the market or simply reflects broader shifts in cheaper, faster development. On policy, the group covers BIO's response to the OMB proposal that could inject political review into federal grant decisions. The co-hosts also debate Kalshi's move to create prediction markets around clinical trial and regulatory outcomes. On pipeline updates, the group discusses Merck's approval of Lipfendra, the first oral PCSK9 drug, and the broader class implications. In CNS, Biogen and Ionis' diranersen tau ASO data spark a discussion of aconfusing dose response, ASO tolerability, tau as a target in Alzheimer's disease, and the promise of alternative modalities from Arrowhead and Alnylam. The episode closes with M&A and financing, including AstraZeneca's licensing deal with Dizal for the EGFR exon 20 inhibitor sunvozertinib andErasca's RAF data plus its $500M financing, which Sam views as a strong market signal despite a volatile biotech backdrop. This episode aired on July 17, 2026.

Nach der Insolvenz von VisioBraille führt die LUCAS components GmbH aus Jena die bekannten Braillezeilen-Reihen weiter. Stephan Merck erklärt im Gespräch, was sich hinter dem Modellen Vario 340 und Vario 540 verbirgt. Im Zentrum steht der neue HID-Braille-Standard, mit dem Braillezeilen künftig ganz ohne spezielle Treiber funktionieren sollen. Merck schildert, wie diese treiberlose Anbindung in der Praxis technisch umgesetzt wird, welche Tasten welche Funktion übernehmen und wo es zwischen JAWS und NVDA noch Unterschiede gibt. Eine Folge für alle, die wissen wollen, wie aus einer Firmeninsolvenz neue, kompatiblere Technik entstehen kann und was der Wechsel zu einem Universalstandard für den Alltag mit der Braillezeile bedeutet.

Wie der Bau am Saladin-Eck in den Ferien weitergeht, Merck eröffnet in Darmstadt ein Prüfzentrum für Arzneimittel und 26-Jährige steht nach der Besetzung der Mathildenhöhe im Februar vor dem Amtsgericht. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: So geht der Bau am Saladin-Eck in den Ferien weiter https://www.echo-online.de/lokales/darmstadt/so-geht-der-bau-am-saladin-eck-in-den-ferien-weiter-5854025 Merck eröffnet Prüfzentrum für Arzneimittel in Darmstadt https://www.echo-online.de/lokales/darmstadt/merck-eroeffnet-pruefzentrum-fuer-arzneimittel-in-darmstadt-5858216 Mathildenhöhe Darmstadt: Osthang-Besetzerin muss vor Gericht https://www.echo-online.de/lokales/darmstadt/mathildenhoehe-darmstadt-osthang-besetzerin-muss-vor-gericht-5875842 Darmstädter Verein besorgt Hilfe für Klinik in Odessa https://www.echo-online.de/lokales/darmstadt/darmstaedter-verein-besorgt-hilfe-fuer-klinik-in-odessa-5873858 Beratungsbedarf bei Darmstadts Senioren bleibt hoch https://www.echo-online.de/lokales/darmstadt/beratungsbedarf-bei-darmstadts-senioren-bleibt-hoch-5855090 Ein Angebot der VRM.

Carl Quintanilla and Jim Cramer explored what to make of the pullback in the AI trade: Taiwan Semiconductor shares dragged the chip sector lower despite the company's record quarterly results. A different story for UnitedHealth Group, up sharply on its blowout earnings and raised guidance. The anchors discussed the SpaceX stock slump one day after shares fell below their $135 IPO price for the first time ever. Also in focus: Earnings movers from GE Aerospace to United Airlines; June retail sales reaction; Uber to buy Germany's Delivery Hero in a $14.8 billion deal; Eli Lilly's psychedelic M&A takeover; FDA approves Merck's new cholesterol pill; Trump Media's new move; Cramer previews the CNBC Investing Club Monthly Meeting.     Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

US equity markets weaker with fresh falls for chip makers overshadowing generally upbeat economic data, down 106 points or 0.2%. Alphabet, Caterpillar and Goldman Sachs all dropping over 4%. On the upside, Nike rallied 4.2%, while Amgen, IBN, McDonald's, Merck & Co, and Salesforce all rallied over 3%.

2000 Quadratmeter groß und 25 Millionen Euro teuer: das neue Testzentrum bei der Firma Merck in Darmstadt mit hochmodernen Laboren und Geräten. Hier sollen Mitarbeiter in Zukunft prüfen können, ob Arzneimittel freigegeben werden können - um sie zu verkaufen. Außerdem: Gegen 1 Uhr brennt in Lampertheim eine Küche. Die Feuerwehr rückt aus zu einem Mehrfamilienhaus in der Alten Viernheimer Straße. Der Küchenbrand wird zügig unter Kontrolle gebracht und der einzige Bewohner der Brandwohnung gerettet. Und: Raunheim plant freiwilligen Ordnungsdienst gegen Vermüllung

US equity markets weekend with fresh falls for chip makers overshadowing generally upbeat economic data, down 106 points or 0.2%. Alphabet, Caterpillar and Goldman Sachs all dropping over 4%. On the upside, Nike rallied 4.2%, while Amgen, IBN, McDonald's, Merck & Co, and Salesforce all rallied over 3%.

What keeps teams stuck in the same conversations without making real progress? In this episode, Kevin talks with Gustavo Razzetti about why teams avoid the conversations that matter most and how leaders can help them move forward. Gustavo shares that silence often happens not just because people feel unsafe, but because speaking up feels pointless when nothing changes. They discuss the difference between backward talk (blame, avoidance, and groupthink) and forward talk, which helps teams address real issues, learn, and act. Gustavo also introduces the idea of conversational debt, the price teams pay for the questions they don't ask, the ideas they don't share, and the issues they avoid. Kevin and Gustavo discuss the three types of this debt: alignment debt, belonging debt, and collaboration debt, and why leaders must continually validate alignment, welcome healthy dissent, and create space for real progress. They also touch on how AI can amplify existing team dynamics, making groupthink and misalignment even more costly. Listen For 0:00 Why teams get stuck and stay silent 0:36 Welcome to the Remarkable Leadership Podcast 1:32 Meet Gustavo Razzetti 2:41 Why Gustavo wrote Forward Talk 4:22 The real reason people stay silent 6:30 Forward talk vs. backward talk 9:01 False harmony and psychological safety 10:56 What is conversational debt? 12:45 Alignment debt 16:12 The illusion of alignment 17:24 Belonging debt 19:17 Collaboration debt 21:17 How AI amplifies team dynamics 25:34 One organizational next step 28:09 What Gustavo is reading 29:01 Where to find Gustavo Razzetti 29:58 Now what? Kevin's closing challenge Gustavo's Story: Gustavo Razzetti is the bestselling author of Remote, Not Distant, Stretch for Change, and his latest book, Forward Talk: The Bold New Method for Getting Teams Unstuck. He is a culture strategist, workshop facilitator, and keynote speaker with over 25 years of experience—first as a marketing and advertising executive, now as CEO of Fearless Culture, a culture design consultancy. He's facilitated more than 1,500 workshops with leadership teams at Mars, Microsoft, Merck, the Inter-American Development Bank, and hundreds of organizations across the world. Razzetti is the creator of the Culture Design Canvas, now used by over 500,000 practitioners worldwide, and the Forward Talk framework. He helps teams surface issues early, challenge groupthink, and turn avoided conversations into decisions that stick. His work has been featured in The New York Times, BBC, Forbes, and Fortune. He's also a regular contributor to Psychology Today. https://gustavorazzetti.com/about/ https://www.fearlessculture.design/about https://www.linkedin.com/in/gustavorazzetti/ Looking to Develop Stronger Leaders? Want help developing the leaders in your organization? Reach out to explore how the Kevin Eikenberry Group can support your team at info@kevineikenberry.com.  Book Recommendations Forward Talk: The Bold New Method for Getting Teams Unstuck by Gustavo Razzetti Remote Not Distant: Design a Company Culture That Will Help You Thrive in a Hybrid Workplace by Gustavo Razzetti Stretch for Change: How To Improve Your Change Fitness And Thrive In Life by Gustavo Razzetti  Meaningful Work: How to Ignite Passion and Performance in Every Employee by Wes Adams and Tamara Myles Like this? The Science of High Performance Teams with Dr. David Burkus Building Emotionally Intelligent Teams with Vanessa Druskat Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group   Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes   

What if some of the greatest investment opportunities weren't hiding in Silicon Valley or Wall Street, but inside small businesses that have been overlooked for decades?In this episode of The Conscious Capitalists, hosts Timothy Henry and Raj Sisodia sit down with Monika Mantilla, Co-Founder, President & CEO of Altura Capital (https://alturacap.com/), to explore how patient capital, purpose-driven investing, and entrepreneurial success can create extraordinary financial returns while strengthening communities. Over the past 21 years, Monika has built a proven track record investing in lower middle market businesses across low-and-moderate-income communities, demonstrating that impact and performance are not competing priorities, but mutually reinforcing ones.Monika shares why Altura Capital was intentionally built as an investment platform rather than a traditional private equity fund, allowing the firm to provide flexible capital tailored to the unique needs of growing businesses. She explains why patient investment horizons of three to seven years, combined with operational partnership and long-term thinking, consistently outperform short-term approaches. Along the way, she introduces The Altura Way, the firm's ten-pillar value creation framework that helps companies strengthen strategy, operations, leadership, governance, digital transformation, and community impact while building more resilient businesses.The conversation also explores one of the largest untapped opportunities in modern investing. Monika discusses research conducted alongside 29 of America's largest corporations that identified an estimated $590 billion in unrealized value within underserved business segments. She explains how diverse ownership, improved market access, and stronger partnerships with companies such as Walmart, Kroger, CVS, Merck, and Johnson & Johnson help unlock growth that traditional investors often overlook.But this episode reaches far beyond investing. Monika reflects on the influence of her upbringing in Bogotá, Colombia, the lasting impact of her mother, her faith-driven approach to leadership, and the philosophy that guides both her life and business: ser en el hacer—being in the doing. She also shares her unique 200-hour planning system, organizing life into fourteen categories across eight-week cycles, and explains why she considers leading Altura to be only her seventh priority after ensuring the rest of her life is aligned with her values.Listeners will gain insights into:Why the lower middle market represents one of the most overlooked opportunities in private equityWhat patient capital really means and why long-term investing creates stronger businessesHow Altura's ten-pillar value creation framework systematically scales growing companiesWhy diverse ownership and investing in underserved communities can generate above-market returnsHow market access and strategic partnerships accelerate business growthWhy values, intentional leadership, and disciplined time management are foundational to long-term successThe role conscious capitalism can play in creating both economic progress and social progressWhether you're an investor, entrepreneur, business leader, or simply interested in how capitalism can be a force for lasting value creation, this episode offers a compelling conversation about building businesses that deliver exceptional returns while expanding opportunity for more people.If you enjoy this podcast, would you consider leaving a review on Apple Podcasts or Spotify? It takes only a few seconds and greatly helps us get our podcast out to a wider audience.Please subscribe on Apple Podcasts / Spotify / Stitcher, or wherever you get your podcasts.For transcripts and show notes, please visit The Conscious Capitalists. This show is presented by Conscious Capitalism, Inc.Chapters0:00 Introduction – Meet Monika Mantilla, Co-Founder & CEO of Altura Capital1:50 What Is Altura Capital? Overview of the Investment Platform3:51 Why "Platform" and Not Just a Fund5:27 Patient Capital: What It Means and Why It Matters7:12 Non-Financial Investment Criteria: Values, Purpose & Impact9:39 The Meaning Behind the Name "Altura" – Height & Vision11:24 Dignity as a Core Value12:52 Women in Finance: The Case for Parity in Capital Allocation15:56 Investing in Overlooked Communities: The Opportunity & the Returns21:41 Track Record & Above-Market Returns23:26 Market Access & Corporate Relationships as a Value-Add26:23 Impact Metrics: Jobs, Communities & the Altura Way36:49 What Made Monika Monika? Roots, Values & Spiritual Foundation41:33 Time Management: The 200-Hour / 8-Week Planning System45:52 Rapid Fire Questions46:05 Favorite Book: The 7 Habits of Highly Effective People

 Many people living with Crohn's disease or ulcerative colitis assume that if symptoms improve, their disease is under control. But with inflammatory bowel disease, inflammation can sometimes continue silently, even when you feel okay. In this episode of Gastro Girl, Jacqueline Gaulin speaks with IBD expert Dr. Jessica Allegretti about what IBD may be affecting inside the body and why symptom relief is not always the same as healing. They discuss the difference between feeling better and achieving remission, why ongoing monitoring matters, how flares can develop, and how proactive care may help protect long-term health. This conversation is designed to help patients better understand what may be happening inside their bodies and feel more informed when talking with their healthcare team. This education initiative is sponsored by Merck.  

What does it take to build healthcare technology that can make vital signs easier to capture, track, and use? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Mitch Foster, founder and CEO of Mindset Medical, to discuss his career in healthcare, medical devices, robotics, and digital health. Mitch shares how his early work ethic and healthcare experience led him from orthopedic sales and executive leadership to building companies at the intersection of medicine and technology. The conversation explores Mitch's path through Merck, DeRoyal, Synthes, NuVasive, and Excelsius Surgical, the spine robotics company acquired by Globus Medical. Mitch reflects on lessons learned from mentors, physicians, strategic partners, and the experience of building and exiting a company before applying those lessons to Mindset Medical. The episode also looks at Mindset Medical's vision to turn the smartphone into a medical device. Mitch explains how the company evolved from digitizing patient intake to developing video-based vital sign technology, including FDA-cleared pulse rate and respiration rate tools, with a path toward non-contact blood pressure measurement. Beyond the technology, John and Mitch discuss telemedicine, rural healthcare, chronic disease management, entrepreneurship, resilience, founder traits, leadership under pressure, and building through pivots and setbacks. Mitch also shares advice for aspiring entrepreneurs: go for it, scenario plan, understand the sacrifice, and remember that time is the most valuable asset we have. About Mitch Foster: Mitch Foster is the founder and CEO of Mindset Medical and an experienced healthcare entrepreneur and medical device executive. His career spans pharmaceutical sales, orthopedics, spine robotics, digital health, and startup leadership. Before founding Mindset Medical, Mitch helped build Excelsius Surgical, a robotic spine surgery company acquired by Globus Medical. About Mindset Medical: Mindset Medical is developing technology designed to turn the smartphone into a medical device. The company's platform uses video-based technology to capture vital signs and support more accessible, data-driven care. With FDA clearances for pulse rate and respiration rate, Mindset Medical is working toward non-contact, non-calibrated blood pressure measurement and broader applications across telemedicine, rural healthcare, and chronic disease management. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund, the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. About Jetstream Venture Fund: Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums ($5,000⁠), and no carried interest. Jetstream is one of the first funds of its kind, bringing venture-style investing opportunities to a wider professional audience. Back-end administration is provided by Sweater Ventures a ground-breaking turnkey fund management company. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing or by visiting the. Please read the prospectus carefully before investing.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Dakota Baptist Convention's new Director, Dr. Lee Merck, delivered this message to Christ Church of Rapid City, SD, on July 12,2026.

Jordan Sather and Nate Prince kick off a slower newsweek by trading MAHA wins (fasting, ankle rehab, and other Friday flexes) before diving into RFK Jr.'s push for a formal COVID vaccine injury table and what it could mean for Americans still waiting on compensation. They break down HHS's new Make Hospital Food Healthier Pledge, wonder aloud why hospital cafeterias so often resemble a sad Applebee's, and dig into Medicare's brand new GLP1 coverage pilot for seniors. After Nate signs off early, Jordan flies solo through Merck's Gardasil settlement, the Supreme Court's glyphosate ruling, and a candid roast of biohacker Brian Johnson's autoimmune diagnosis. The episode wraps with a genuinely useful rundown of habits and supplements for focus and ADHD, from Lion's Mane to adaptogens. Equal parts news update and dinner table debate about what actually counts as "good" food.

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with Erin Gillaspie, MD, MPH, and Laurie Matt-Amaral, MD, MPH, about navigating challenges as women in oncology, investing in relationships and more. ·       Gillaspie and Matt-Amaral share their journeys within their fields. 2:37 ·       Have you ever experienced imposter syndrome? 9:26 ·       How did you navigate moments when it felt like you had hit a wall? 10:36 ·       How have you balanced family life and your career? 21:25 ·       If you had to give two or three tips for up-and-coming women physicians, what would they be? 30:07 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Gillaspie can be reached at eringillaspie@creighton.edu or on Instagram @dreringillaspie. Matt-Amaral can be reached at mattaml@ccf.org. Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.

Are you considering whether an MBA is worth it in 2026? Shari Hubert is the Associate Dean of Admissions at Duke's Fuqua School of Business, where she has led admissions since 2017. With previous leadership roles at Georgetown University, the Peace Corps, and major companies including General Electric, Citigroup, Boston Consulting Group, and Merck & Co., she is passionate about expanding access to MBA education and helping future business leaders achieve their goals. In this episode, Shari talks about student life, knowledge, and how alignment with culture and values plays a vital part in your MBA decision.  Achievable GRE uses AI-powered adaptive learning to target your weak areas and boost your score - visit https://achievable.me/exams/gre/overview/#s=podcast to try it for free.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What happens when an architect's structured world collides with the freedom of art—and grief becomes the bridge between them? In episode 268, Ksenia Merck shares how illustrating Ghost Flower, the novel her late husband Bill left behind, turned heartbreak into a sweeping collaboration of love, art, and legacy. For Ksenia, the journey wasn't about letting go—it was about discovering that connection, like the cosmos she paints, simply continues.In This Episode, You Will Learn:(03:58) Ksenia's warm welcome and the story behind Ghost Flower(04:19) How she balances two worlds: architecture and art(05:29) The origin of Ghost Flower's cover and Bill's final days(09:07) Sketching the cosmos: bringing the novel's imagery to life(11:00) Creating The Ghost Flower Companion Journal(12:43) Remembering Bill: her "twin flame" and exceptional soul(17:51) Finding cosmic wonder in the night sky(19:39) Art as liberation: healing through creative freedom(22:38) Layered loss: navigating grief at her own pace(24:52) A mini life review: recording Bill's books and writing her ownKsenia J. Merck is an artist, architect, and creative storyteller whose work bridges structure, imagination, and spirit. After four decades managing airport capital programs, she turned to art after the unexpected passing of her husband, William F. Merck II, illustrating and posthumously publishing his science fiction novel, Ghost Flower, and later creating its companion journal. Drawing on her travels, marriage, and fascination with the cosmos, her work explores connection, resilience, and the continuum between life and loss. Originally from Arizona and now in Florida, she shares her story of grief, healing, and creative reinvention.In this episode, Ksenia opens up about the dual nature of her life — decades in the structured world of architecture, set against the liberating world of art. She shares how illustrating Ghost Flower became both a tribute to Bill and a path through grief, describing the immersive process of sketching the novel's imagery and how those sketches led to The Ghost Flower Companion Journal. She speaks tenderly about Bill as her "twin flame" and a compassionate leader, and about layered loss — her mother, her father, and then Bill — admitting to "blowout" days while coming to believe grief isn't an ending but a continuum she still feels connected to. She closes by sharing she's recording audiobooks of Bill's books, writing her own story, and points listeners to her website and Instagram.Connect with Ksenia J. Merck: WebsiteLinkedInInstagramFacebookGet Ksenia's books!Let's Connect:WebsiteInstagram Hosted on Acast. See acast.com/privacy for more information.

Watch the show on television by downloading the SuperCrowd.tv Channel app to your Roku or Amazon Fire TV and e360tv channel app to your Roku, LG or Amazon Fire TV. You can also see it on YouTube.Devin: What is your superpower?Daniel: Combination of curiosity and humility.What if a single treatment could extend the length and quality of your life—or the lives of your beloved pets? Daniel Oliver, Co-Founder and CEO of Rejuvenate Bio, believes it's possible and is already making it a reality. Rejuvenate Bio has developed a breakthrough approach, beginning with pets, to address multiple chronic diseases with one therapy.“We actually have taken the wealth of aging science that's out there,” Daniel explained, “and have been able to turn them into one-time therapies. Effectively, we're able to inject a patient—whether it's a dog, a cat, or a human—and the data suggests we can treat multiple different diseases.”Daniel shared his excitement about testing these therapies on animals, highlighting initial successes with several high-profile pharmaceutical companies, including Merck's animal health division, which has also invested in the company. Early results show these treatments not only improve health outcomes but also have the potential to be safe, accessible, and affordable.Unlike traditional gene therapies for humans, which can cost millions, Rejuvenate Bio's approach for animals carries a dramatically lower price tag. “We've reduced the manufacturing costs to the point where we can treat chronic, lifetime diseases at around $100 per dose,” Daniel said. This affordability has broad implications for human treatments too, ensuring accessibility beyond just the wealthy elite.Beyond the practical applications, the mission of Rejuvenate Bio is deeply human. Chronic diseases, Daniel noted, account for enormous healthcare costs and significant suffering. He envisions a future where people and pets alike can experience more healthy years together. “What if,” he posed, “instead of a laundry list of side effects, new treatments came with a list of novel benefits?”Rejuvenate Bio is currently hosting an equity crowdfunding campaign on Wefunder, inviting anyone to invest and be part of their journey. This move aligns with Daniel's vision of building a community of supporters who share the mission. “We want folks to come in, become evangelists for our technology, and grow with us,” he said.tl;dr:Daniel Oliver discusses Rejuvenate Bio's one-time treatments for pets to extend healthy lives.The therapies have shown promise for treating chronic diseases in animals and potentially humans.Daniel shares Rejuvenate Bio's affordability strategy: manufacturing doses for as low as $100.Rejuvenate Bio's recent partnerships with Merck and a live Wefunder campaign expand their impact.Daniel explains how curiosity and humility fuel his leadership at Rejuvenate Bio, emphasizing collaboration.Daniel's company offers exciting hope—not just for the families whose pets will lead healthier lives, but for society as it considers how this innovation could reshape human healthcare.How to Develop Curiosity and Humility As a SuperpowerDaniel attributes his success to a combination of curiosity and humility. “When you're doing these types of startup companies, you're never going to come to the table with all the skills and experiences you need,” Daniel said. His curiosity drives him to seek knowledge and advice, while his humility allows him to admit there is always more to learn. By embracing these values, Daniel has built an adaptable, reflective leadership style that encourages innovation and resilience.Daniel's humility and curiosity were tested during his time at Caltech, where the demanding academics overwhelmed him. He learned to collaborate with peers and seek help from teaching assistants to overcome challenges. “The homework problems were not something I could accomplish alone,” he admitted, emphasizing how teamwork and the willingness to learn built his resilience. This experience taught him to embrace failure as a learning opportunity—something he carries into his leadership at Rejuvenate Bio.Tips for Developing This SuperpowerDiscipline Yourself to Listen: Focus on understanding the full message rather than preparing an immediate response.Be Open to Feedback: Acknowledge that there's always a better way and commit to continuous improvement.Embrace Collaboration: Recognize that achieving great things often requires the strengths of a team.Seek Expertise: Learn from others with specialized knowledge, even when you succeed.Live and Learn: Foster a culture where risk-taking is encouraged and failures become growth opportunities.By following Daniel's example and advice, you can make curiosity and humility a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDaniel Oliver (he/him):Co-Founder & CEO, Rejuvenate BioAbout Rejuvenate Bio: Rejuvenate Bio is targeting the core drivers of chronic age-related diseases by unlocking the power of gene expression and epigenetic reprogramming to reverse pre-existing heart disease, metabolic disease, and kidney failure in humans.Website: rejuvenatebio.comCompany Facebook Page: facebook.com/RejuvenatebioCompany Twitter/X Handle: @rejuvenatebioLinkedIn Profile: linkedin.com/company/rejuvenate-bioOther URL: wefunder.com/rejuvenatebioBiographical Information: Daniel Oliver is a biotechnology entrepreneur and gene therapy innovator dedicated to transforming breakthrough aging science into life-changing therapies for animals and people. As Co-Founder and CEO of Rejuvenate Bio, a company spun out of Harvard Medical School and Wyss Institute for Biologically Inspired Engineering, he is leading the development of one-shot gene therapies that target the root causes of age-related cardiac and metabolic diseases. Under his leadership, Rejuvenate Bio has secured significant equity and non-dilutive funding, advanced novel gene therapy platforms toward clinical development, and established strategic partnerships with leading animal health companies to accelerate innovation in both veterinary and human medicine.Before founding Rejuvenate Bio, Daniel co-founded Voxel8, a pioneering 3D printing company that raised more than $14 million, launched groundbreaking products, and was ultimately acquired by Kornit Digital. Voxel8 earned widespread recognition, including being named one of MIT Technology Review's “50 Smartest Companies” and a Top 9 Innovation at CES. Daniel also serves as an Entrepreneur in Residence at University of California, San Diego, where he mentors researchers and founders in commercializing breakthrough technologies. A graduate of Harvard Business School and California Institute of Technology, he combines deep scientific expertise with entrepreneurial leadership to bring cutting-edge biotechnology from the laboratory to the marketplace.LinkedIn Profile: linkedin.com/in/danielcoliverSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include Cineblock Films and Climatize. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Babbit | Coledger Solutions | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Join the SuperCrowd Impact League! You can be recognized for making impact investments via Reg CF. See how your activity compares to your peers. It's free. Win valuable prizes. Start now!SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on July 14th at 8:00 PM ET/5:00 PM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour, July 15, 2026, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “How to Make a Splash With Your Campaign Launch.” Drawing on his extensive experience helping entrepreneurs and impact-driven founders succeed in investment crowdfunding, Devin will share proven strategies for creating momentum and attracting attention when launching a crowdfunding campaign. In this session, he'll explore how founders can prepare for a successful launch, build excitement before going live, engage their networks effectively, and generate the early traction that often determines long-term campaign success. Attendees will learn practical tactics for storytelling, outreach, media engagement, and community building, along with common mistakes that can limit visibility and investor interest. Whether you're preparing for your first crowdfunding raise or looking to improve the performance of a future campaign, this SuperCrowdHour will provide actionable insights to help you launch with confidence and maximize your campaign's impact from day one. Register now!SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Register Now! October 20th and 21st will be the Crowdfunding Professional Association Regulated Investment Crowdfunding Summit for 2026. This is the event of the year for everyone in the crowdfunding ecosystem.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We share educational information—not investment advice. Some links may generate compensation. See our full disclosure.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In today's show, Mark talks with Joe Vaillancourt of Winfield United at a recent field day, Riley learns about a new vaccine device with Dr. Abbie Redalen of Merck, and Dustin visits with House Ag Committee Ranking Member Angie Craig.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/emerging-agents-in-pulmonary-arterial-hypertension-10829Program DescriptionThis enduring educational activity provides a comprehensive update on late stage agents being researched for the management of pulmonary arterial hypertension (PAH). Led by expert faculty, the program shifts the clinical focus from traditional vasodilators to novel investigational therapies that directly target the underlying cellular pathways responsible for pulmonary vascular remodeling and disease progression. Clinicians will gain critical insights into the mechanisms of action, latest clinical trial data, and real-world practice implications of these emerging therapeutic classes to better address unmet needs in contemporary care.At the conclusion of this activity, participants should be better able to:Discuss clinical trial data and potential clinical utility of emerging agents in PAH.Accredited ProvidersThe National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).Accreditation StatementThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Intended AudiencePulmonology clinicians (physicians, nurse practitioners, and physician associates), cardiology clinicians, and primary care clinicians caring for patients with or at risk for PAH.FacultyIoana Preston, MDDirector Pulmonary Hypertension CenterLahey Hospital and Medical CenterUMASS Chan Medical SchoolBurlington, MADr. Preston has disclosed the following financial relationships:Consultant: Gossamer Bio, Insmed, Janssen Pharmaceuticals, Keros Therapeutics, Liquidia Technologies, Merck & Co./Acceleron Pharma, Respira Technologies, United Therapeutics CorporationContracted Research: Gossamer, Janssen Pharmaceuticals, Merck & Co./Acceleron Pharma, Novartis, United Therapeutics CorporationData and Safety Monitoring Board (DSMB): Tectonic TherapeuticAll of her disclosures are related to PH.Jean Elwing, MDProfessor of Medicine, University of Cincinnati College of MedicineDirector, Pulmonary Hypertension Program, University of Cincinnati Pulmonary, Critical Care and Sleep MedicineCincinnati, OHDr. Elwing has disclosed the following financial relationships:Consultant: Gossamer Bio (pulmonary hypertension), Insmed (pulmonary hypertension), Liquidia (pulmonary hypertension), United Therapeutics (pulmonary hypertension)Speaker: Merck (pulmonary hypertension)Contracted Research: Acceleron/Merck (pulmonary hypertension), Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Insmed (pulmonary hypertension), Lung LLC (pulmonary hypertension), Novartis (pulmonary hypertension), NS Pharma (pulmonary hypertension), Pharmosa/Liquidia (pulmonary hypertension), Pulmovant (pulmonary hypertension), Regeneron (pulmonary hypertension), United Therapeutics (pulmonary hypertension)These relationships ended within the last 24 months:Consultant: Inhibikase (pulmonary hypertension), Janssen/Actelion/Johnson & Johnson (pulmonary hypertension), Merck (pulmonary hypertension)Advisor/Advisory Board: Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Merck (pulmonary hypertension), United Therapeutics (pulmonary hypertension)Speaker: United Therapeutics (pulmonary hypertension)All of the relevant financial relationships listed for these individuals have been mitigated.Nurse Planner and Peer ReviewerMarjorie Crabtree, DNP, FNP, ANPHaymarket Medical EducationSteering CommitteeNurse Practitioner Healthcare FoundationAccredited Provider Program DirectorBellevue, WADr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.Accredited Provider DisclosureNACE staff have no relevant financial relationships to disclose.Commercial SupportersThis activity is supported by an independent educational grant from Insmed and an independent educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Julián Coca, asesor de inversiones de Alterarea, comparte su análisis cobre qué esperar de los resultados de Nike, sobre Merck y AbbVie y Sandisk.

She Moved to the US with $800, Changed Her Name to Fit In, and Built a Career at Merck, Oracle, Tableau, and Amazon. Helen on Going From Terrified to Outspoken Her legal name is Hongyi, which means "the water is deep and wide." When she moved to the United States from China, she changed it to Helen so people could pronounce it more easily. She arrived with $800. She was terrified. At grad school, she barely had to speak. Then she entered the workforce. Her first significant feedback at Merck: "You need to improve your communication." She was too intimidated to ask what that meant. So she made assumptions, started listening to radio broadcasts during her long New Jersey to Pennsylvania commute, and repeated every word she heard, even when she didn't know what some of them meant. She also completely changed how she structured her thinking: lead with the statement, give details only if someone asks. Helen is now Head of Data Analytics Partner GTM at Amazon Web Services. She has built her career across Merck, Oracle, Tableau, and AWS, switching domains multiple times from chemist to engineer to customer management to partner sales. In this episode, she breaks down exactly how she got here. You'll learn: Why she was too scared to ask her first senior leader what "improve your communication" actually meant, what assumptions she made instead, and how that experience shaped the way she now gives and asks for feedback. The Oracle account management idea she developed during the 2008 financial crisis, why she had no idea who to pitch it to, and what happened when she decided to pitch it to everyone who would listen: "I talked to anyone and anyone. And it worked." How that pitching-to-everyone strategy led her to the sponsor who first backed her idea, then backed her career, and why she believes sponsors select you rather than the other way around. The three factors she attributes to attracting a sponsor: visibility (being seen under pressure), adding value to the sponsor specifically, and consistency doing simple things reliably rather than many things sporadically. The senior Oracle executive who told her "everything can be simplified into three bullet points" and why that one insight transformed how she communicated with leadership for the rest of her career. What it actually looked like behind the "fast career" others saw from outside: 15-hour days, PowerPoint decks rebuilt at 4am and still not good enough, and switching domains so many times she felt perpetually behind. Why she credits letting other people shine and giving credit generously as one of the most underrated career moves she made, and how she discovered it mattered more than she expected. Her three closing principles: know your superpower, find your passion, and pay it forward because we have all been helped up the ladder at some point. About Helen: Head of Data Analytics Partner GTM at Amazon Web Services, Helen has built her career across Merck, Oracle, Tableau, and AWS, moving from chemistry to computer engineering to enterprise sales to partner leadership. An immigrant who arrived in the US with $800, she now mentors and sponsors others on the same journey.

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech. He is joined by Kaleem Chowdhury, Ph.D., CEO of Haiku Biosciences; Liz Leveille, who leads the Boston Innovation Hub and discovery transactions at Merck; and Abbas Kazemi, CEO of Nimbus Therapeutics. The panel digs into the realities behind the headlines, from investor scrutiny and platform company pressure to China’s growing role in licensing and the long relationship-building that often happens before a deal gets done. To learn more about the topics in this episode: March M&A surge triggers high expectations for 2026 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought? This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über eine milliardenschwere Übernahme von Merck, einen verhängnisvollen Preissprung bei Apple-Geräten und die 2000-Prozent-Rallye von SanDisk. Außerdem geht es um Amazon, Alphabet, Meta Platforms, Micron Technology, Samsung Electronics, SK Hynix, Qualcomm, Corning, Lockheed Martin, Allianz, Fresenius Medical Care, DHL Group, Merck KGaA, Bio-Techne, Bayer, Rheinmetall und Alibaba. Abonniert unter diesem Link den neuen „Cashburners: Die Lilium-Story“-Podcast von Gründerszene.https://open.spotify.com/show/0I11ZJnhbqX6o9TQb3c1X6 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements. Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck's most significant deal since purchasing Sigma-Aldrich in 2015, reinforcing its strategic focus on expanding its life sciences tools portfolio. The acquisition aims to accelerate innovation in drug development and diagnostics, highlighting Merck's commitment to enhancing its capabilities in biotechnology under the leadership of CEO Kai Beckmann. Such strategic moves underscore a broader trend towards bolstering biotech portfolios through mergers and acquisitions as companies aim to remain competitive in an ever-evolving market landscape. In regulatory news, the FDA has approved a pioneering combination therapy involving Gilead's Trodelvy and Merck & Co.'s Keytruda for the first-line treatment of triple-negative breast cancer (TNBC). This aggressive cancer subtype has historically had limited treatment options, making this approval particularly significant. The combination therapy leverages an antibody-drug conjugate targeting Trop-2 alongside a PD-1 inhibitor, offering a promising new strategy that could substantially improve patient survival outcomes. This development also highlights the growing role of antibody-drug conjugates in oncology, illustrating how innovative therapeutic combinations can enhance treatment efficacy. Meanwhile, Pfizer's Ibrance has received FDA approval for label expansion to treat HR-positive, HER2-positive metastatic breast cancer. As a CDK4/6 inhibitor crucial in cell cycle regulation, Ibrance's expanded use reflects ongoing advancements in targeted therapies that personalize cancer treatment based on specific molecular characteristics. Such expansions demonstrate the importance of continuous clinical evaluation and regulatory engagement in extending the lifecycle and applications of existing drugs. Ionis Pharmaceuticals has gained FDA approval for Tryngolza for severe hypertriglyceridemia, marking a significant milestone for antisense oligonucleotide therapies. By targeting apolipoprotein C-III, Tryngolza offers a novel approach to managing metabolic conditions linked to pancreatitis risks. This approval underscores the growing importance of antisense technology in addressing complex lipid disorders and highlights Ionis' strategic efforts to expand market reach through global partnerships. On the business development front, Boehringer Ingelheim's partnership with Immunai aims to leverage artificial intelligence in T-cell target discovery for cancer and autoimmune diseases. The integration of AI/ML technologies into drug discovery processes is increasingly seen as essential for enhancing precision and efficiency. This collaboration reflects an industry-wide shift towards embracing technology to improve research and development outcomes. In clinical trials, Otsuka's centanafadine shows promise for adults with ADHD and comorbid anxiety following successful Phase 3b trials. As a small molecule reuptake inhibitor, centanafadine could provide dual therapeutic benefits for patients with these overlapping conditions. Such developments highlight ongoing innovation in neuropsychiatric treatments aimed at addressing mental health conditions with greater precision. Financially, Oblenio Bio's $62 million Series B funding round will support advancing its tri-specific autoimmune T-cell engager into trials, potentially offering new solutions for autoimmune diseases through innovative immunotherapy approaches. These financial movements illustrate how companies are strategically positioning themselves to capitalize on emerging therapeutic opportunities. Amid these developments, regulatory dynamics continue to evolve, as seen with the FDA's pilot program aimed at streamlining drug approval processes. Initiatives like these are pivotal in restoring confidence in regulatory frameworks while adapting to new scientific insights and technological advancements. Overall, these developments underscore the pharmaceutical and biotech sectors' dynamic nature, characterized by strategic collaborations, regulatory milestones, and innovative treatment options poised to enhance patient care and strengthen drug development pipelines. The ongoing integration of cutting-edge technologies such as AI signifies an evolution towards more personalized and efficient healthcare solutions. Thank you for tuning into Pharma Daily, where we bring you the latest insights from the forefront of pharmaceutical and biotech innovation. Join us next time as we continue to explore the trends shaping the future of healthcare globally.Support the show

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate und auf der hauseigenen European Investor Exchange, die genau auf Privatanleger zugeschnitten ist. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Bayer springt 20% nach Glyphosat-Urteil. Merck kauft Bio-Techne für 11 Mrd. $. Micron legt zu. Qualcomm liefert an Meta. Apple hebt Preise um 20%. Polestar fliegt aus den USA. VW verkauft Motorensparte. XPEL (WKN: A2PN36) war mal eine 100.000% Aktie. Jetzt stagniert das Wachstum, die Marge soll sich aber bis 2028 verdoppeln. Kommt das Comeback beim Lackschutzfolien-König? Medtronic (WKN: A14M2J) meldet das stärkste Wachstum seit zehn Jahren. Die Herz-Ablation boomt, der OP-Roboter Hugo greift Intuitive Surgical an. 3,5% Dividendenrendite bei einem KGV von 14. Diesen Podcast vom 26.06.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, and strategic collaborations. One of the more controversial events involves the retraction of a high-profile study in Nature Medicine. This study initially suggested that the timing of PD-1 inhibitor administration had significant impacts on survival rates for non-small cell lung cancer patients. Early-day administration was linked to improved outcomes compared to later in the day. However, after a four-month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abbisko Therapeutics to harness Abbisko's drug discovery capabilities, particularly in oncology. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment, Foundayo, in Europe, as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. This underscores a broader challenge within the industry: balancing pricing regulations with expanding access through digital health channels like telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody-drug conjugate, Zynlonta, by reducing its workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opzelura highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure, Advancell's move to establish its U.S. headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry-wide push towards exploiting cutting-edge technologies like AI-driven drug discovery to meet unmet medical needs in oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with AlzPath to develop blood-based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Serapha Bio's public debut through a reverse merger with Boundless Bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations. In oncology, Eli Lilly's extended partnership with Abbisko Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas' Padcev combined with Merck & Co.'s Keytruda for muscle-invasive bladder cancer treatment based on promising Phase 3 results. Ophthalmology research is also seeing substantial investment with Ollin Biosciences raising $330 million in Series B funding aimed at developing therapies that challenge existing treatments like Vabysmo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age-related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms, and regulatory milestones that collectively drive forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting-edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.Support the show

In this episode, I share an interview with Evan Unger, who is a change leader with expert facilitator that helps leaders transform their virtual teams to dramatically increase collaborative decision-making, buy-in and results. He shares his professional journey from a leadership role at Merck to becoming an expert in collaborative leadership and facilitation. He introduces Continue Reading

This episode of TriloTalk explores how health literacy goes far beyond simplifying language. It requires consistency, testing, and truly meeting patients where they are. Poor communication can have serious consequences, from medication misuse to reduced trust and engagement in clinical trials. Lisa Chamberlain James, Senior Partner at Trilogy, Elizabeth Brown, Executive Director Clinical Transparency at Merck, and Maureen Kashuba, Senior Director Health Literacy at Merck, discuss this and the importance of partnering together, regardless of what organization you are a part of, to best serve patients across the world. 

Rashmi Airan had it all—an Ivy League education, a successful law career, and a bright future.Then everything changed.After becoming entangled in a mortgage fraud scheme during the housing boom, Rashmi faced federal prosecution, prison, and the public collapse of the life she had spent decades building.But prison did not become her ending.Today, Rashmi is a globally recognized keynote speaker who has spoken for companies including Coca-Cola, Deloitte, Merck, Comcast, Caesars Entertainment, Hershey's, and GE Healthcare. Through her Rise Through It® framework and her new book ALL RISE, she helps leaders transform adversity into courage, accountability, and growth.In this unforgettable conversation with Brent Cassity, Rashmi shares her journey from ambition and success to failure, prison, and ultimately purpose.This is a story of owning your mistakes, rebuilding trust, and discovering that your worst moment does not have to define your future.Show sponsors: Navigating the challenges of white-collar crime? The White-Collar Support Group at Prisonist.org offers guidance, resources, and a community for those affected at prisonist.org. Protect your online reputation with Discoverability! Use code NIGHTMARE SUCCESS for an exclusive discount Visit Discoverability.co. Auto Plaza Direct "Your personal car concierge!" Let them handle every detail to find your perfect car autoplazadirect.com. Author Saffron Gustafson www.mynameissaffron.com, "My Name is Saffron." Author Nevin Shetty, "Second Chance Economics: How Hiring The Formerly Incarcerated Can Unlock $1 Trillion in GDP." www.secondchanceeconomics.com

TODAY ON THE ROBERT SCOTT BELL SHOW: Voters Against Toxic Pesticides, Lisa Rooney, Homeopathy, Summer Remedies, Acid Reflux, Merck Ignored Gardasil Safety Warnings, FDA Scrutinizes Moderna's Flu Data, Radiation Cancer Study, Trust in CDC Collapses, Health Marker Coercion, and MORE! https://robertscottbell.com/voters-against-toxic-pesticides-lisa-rooney-summer-remedies-acid-reflux-follow-up-question-merck-ignored-gardasil-safety-warnings-fda-scrutinizes-modernas-flu-data-low-dose-radiation-cancer-st/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

Let’s Make a Deal! News Dominated by … SpaceX This week – Fed rate Decision Need a new CTP (SPACEX?) PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Let's Make a Deal! - News Dominated by ... SpaceX - This week - Fed rate Decision - Need a new CTP (SPACEX?) Markets - Another V Formation - Nearing Highs again - IPO Madness - Anthropic and OpenAi - SpaceX IPO - could drain markets - More AI valuations through the roof DEDICATION: Stu Schifter - my good friend of 30 years passed away last night... battled Cancer for 2 years. Market Valuations - S&P 500 Forward P/E = 22.5 - 10-yr average =  19–20x - Long-term average 18-19 - Not cheap, pricing in a lot of earnings growth. - NASDAQ 100 forward P/E =  23-24 - 1-yr average   ~23x - 20-yr average  ~20–21x - Not screaming expensive on a forward basis - - NOTE: Training P/E = 33-40 NEW Playbook - But the Rumor and Buy the News - used to be Buy the Rumor and Sell the News - This is why there is an announcement about something and then a date to follow.... - Monday = Deal, Friday = signing On that note - What is the deal anyway? - Seems that we  (USA) moving out our navy before the final - Straights of Hormuz opening -?? - Has anyone seen the text? - We are no better than we were before all this started... Headline Nonsense - Fox Business: Beware the ticking time bomb hiding in your 401(k) - Required minimum distributions can trigger taxes on Social Security benefits and boost Medicare premiums - This is not a ticking time bomb. This is just reality when you have a lot saved and need to start withdrawals - HOWEVER - there are ways around this and we have helped clients with this. - - Listeners - if you have a 401k and think that you will be paying too much later on - we can take a look at the options... More Retirement Alerts - Social Security running out again.... - Less that 10 year until the reserves are exhausted - The Social Security Administration's newly released 2026 Trustees Report confirms that the federal retirement safety net is less than seven years away from fiscal depletion, as the Old-Age and Survivors Insurance (OASI) trust fund will completely exhaust its accumulated reserves in the fourth quarter of 2032. - Once the reserve dries up, ongoing tax revenues will cover only 78% of scheduled retirement benefits, according to the report. - Some of the blame is being laid on the OBBBA with higher standard deductions and lower taxes on SS Benefits - "The OBBBA also adds a temporary additional standard deduction for taxpayers over age 65," it says. "As a result, less income tax will be paid on Social Security benefits, and the OASI and DI Trust Funds will receive lower levels of revenue in the future from income taxation of Social Security benefits." PSA - The Food and Drug Administration (FDA) has classified a recall of more than 900 cases of Alfredo sauce at its highest risk level after a supplier recalled a dry milk powder ingredient used in the product due to potential salmonella contamination. - The FDA designated the recall as a Class I event, its most serious classification, meaning there is a reasonable probability that use of or exposure to the product could cause serious adverse health consequences or death. - The Coffee Connexion Co., Inc. - According to the FDA, the product was distributed in Alabama, Arkansas, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, Nebraska, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin and Wyoming. Monday Markets - 5:45PM Sunday night we see an announcement that there is a Deal! - Why 5:45PM???????? - Futures rally, oil drops - This is just days after the market already surged after a Truth Social post last Thursday that said that the US will "soon" sign a deal with IRAN ---- That pushed up markets quite a bit too - Buy the rumor and buy the news... Reality Check - Thursday: Trump told reporters in the Oval Office that “we have a deal that Iran will never have a nuclear weapon.” - Monday: 60-day period delay to continue discussions of nuclear issues - Is there a sucker in all of this? $ for IRAN - Supposedly there i some deal... - A $300 billion private fund designed ?to trigger investment into Iran is outlined in the U.S.-Iran framework agreement and more than half that sum has already been committed, a source with ?direct knowledge of the deal told Reuters. - The fund is designed to give both sides an economic incentive to conclude a final deal, said the source, who spoke on condition of anonymity because the plan has not yet been announced as Washington and Tehran prepare to sign on Friday. SpaceX - IPO - Finally! $135 per share - Rose to $160+/- on the debut day - Rather smooth process and very orderly - A total of $85B was raised - due to an add-on additional green-shoe that was allowed ($10B) for institutions. - Rose another $20% on Monday - Retail got about 20% of the deal (down from 30%) Oracle - Oracle Corp. shares declined after the company reported quarterly capital expenses that were higher than estimates, raising investor concerns about the profitability of the AI infrastructure business. - The company expects to spend about $70 billion on net capital expenditures in the current fiscal year, and plans to raise another $40 billion in equity and debt. - Oracle's cloud infrastructure business gained 93% to $5.8 billion, and total cloud revenue is projected to jump about 61% in the quarter ending in August. - The increase of $5B over the course of the year was disconcerting to investors. - Shares dropped the most in over 6 months on the news CPI and PPI - May CPI was mixed but generally cooler on the core reading, with headline CPI up 0.5% month-over-month, matching consensus, while Core CPI rose 0.2%, below the 0.3% consensus and below Briefing's 0.4% estimate. - The softer core CPI reading suggests some easing in underlying consumer inflation pressures, which is the more constructive part of the inflation picture. - May PPI was firmer than expected on the headline reading, with PPI up 1.1% versus 0.7% consensus and 0.8% Briefing estimate, matching the prior month's revised 1.1% pace. - Core PPI rose 0.4%, matching consensus and coming in below the prior month's revised 0.7%, indicating wholesale inflation remained elevated but did not accelerate further on the core measure. - Taken together, the CPI and PPI reports point to a mixed inflation backdrop: consumer-level core inflation looked somewhat better, but producer-level price pressures remained sticky. Cyberdyne - Anthropic announced Claude Fable 5, a Mythos-class model that will be available to its enterprise customers and paid subscribers. - The company unveiled Mythos in April and has limited the rollout because of its advanced cybersecurity capabilities. - Anthropic said Claude Fable 5?s broad release is possible because of new safeguards that block responses in specific high-risk areas. - WAIT! The US government PULLED the plug on Mythos and Fable for any foreign national - From Anthropic - The US government, citing national security authorities, has issued an export control directive to suspend all access to Fable 5 and Mythos 5 by any foreign national, whether inside or outside the United States, including foreign national Anthropic employees. The net effect of this order is that we must abruptly disable Fable 5 and Mythos 5 for all our customers to ensure compliance. Access to all other Anthropic models will not be affected. OpenAi - Confidentially flies for IPO - Sends financials and IPO materials to regulators - making sue all in good order. - This allows the company to iron out accounting, compliance, and regulatory issues in private without triggering a "media circus" or alerting competitors to their financials Last Friday..... - Nonfarm payrolls jumped a seasonally adjusted 172,000 for the period, down slightly from the upwardly revised 179,000 in April and far above the Dow Jones consensus estimate for 80,000. - The unemployment rate held steady at 4.3%, as expected. - Average hourly earnings rose 0.3% for the month and were up 3.4% over the past year, both in line with the Wall Street consensus. Screwworm - The New World screwworm has been detected in a 3-week-old calf in Zavala County, Texas, the first known case of that fly in the United States since 2017. - New World screwworm larvae “burrow into the flesh of living animals, causing serious damage to livestock and economic losses,” the U.S. Department of Agriculture said. - The USDA and Texas officials are taking immediate action to contain and eradicate the pest. - In December, the Food and Drug Administration granted conditional approval to the topical solution Exzolt Cattle-CA1, which is used to prevent and treat New World screwworm infestations and is produced by Merck & Co. - What is going to happen to beef prices? Real Estate - Nationwide, 5.8% of all home listings were pulled off the market in April, according to Redfin. - Delistings were up 3.8% compared with March. - Atlanta saw the highest share of homes come off the market in April, with 1 in 10 delisted. San Jose, California, followed with roughly 9% pulled, then Los Angeles (7.8%), Dallas (7.8%) and Seattle (7.7%).  In other news.... - The Japanese city of Utsunomiya has suspended all 94 of the primary and middle schools ?that it operates on Monday after its ?first-ever bear sighting, a municipal official said. - The city of half-a-million residents about 100 km (60 miles) north of Tokyo said ?the bear was first seen in a residential ?area near a park on Saturday evening. It ?remains at large after the last sighting early ?Monday morning about half a kilometre from a ?middle school.   Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); The Winner for the THE CLOSEST TO THE PIN for SALESFORCE (CRM)   Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

“The Cost Of Conversational Debt” Join me and my guest Gustavo Razzetti (https://gustavorazzetti.com), a culture change instigator, speaker, and CEO of Fearless Culture, a culture design consultancy. He helps leaders build teams that talk about what matters—even when it's uncomfortable. His real-life insights come from leading more than 1,500 workshops with teams at Mars, Microsoft, Merck, Globant, and the Inter-American Development Bank. A regular contributor to Psychology Today, his work has been featured in The New York Times, BBC, and Forbes. He is the author of Remote, Not Distant and Stretch for Change. His newest book is Forward Talk: The Bold New Method For Getting Teams Unstuck. Gustavo helps teams say what everyone's thinking but no one's saying. SHOW NOTES SPONSORED BY: Soul of Business™ Experience Find out more at https://bit.ly/SOBECommunity   Summary Explore the transformative power of effective communication and culture in organizations with Gustavo Razzetti, author of Forward Talk. Discover how mastering conversational depth, trust, and addressing conversational debt can unlock team potential and foster a thriving organizational culture. Key Topics The role of communication in organizational culture The concept of conversational debt and how to address it Building trust within teams and organizations The importance of masterful communication and conflict management  Takeaways Effective communication is the foundation of organizational success. Conversational debt accumulates when conversations are avoided or misunderstood. Building trust requires intentional actions and positive requests. Cordial harmony can mask underlying issues that weaken teams. Small, forward-moving actions can start transforming organizational culture. Learn more about your ad choices. Visit megaphone.fm/adchoices

Samuel Brotkin, PhD, Chelsea Kaye, LCSW and Elissa Baldwin Recorded onsite at CancerCon®, a young adult cancer conference presented by Stupid Cancer®, we talk about what resilience really means after a cancer diagnosis, and why it's not about always being “strong.” Join us alongside Sam Brotkin, PhD, a clinical psychologist at Bull City Behavioral Health and Chelsea Kaye, LCSW, an Information Specialist at Blood Cancer United. In this episode, we share compassionate, practical strategies for building lifelong resilience. Learn how to manage expectations, find trusted support, and give yourself grace exactly where you are today. Although this discussion comes from a young adult cancer conference, the insights shared are relevant across all ages and experiences. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Information Specialists Young Adult Resources Young Adult Online Chat Bobby's Coaches Stupid Cancer The Bloodline Live: Emphasizing the Patient Voice in Young Adult Cancer Care – featuring Dr. Abby Rosenberg Additional Blood Cancer United Support Resources: Financial support Free Nutrition Consultations Clinical Trial Support Center Free telephone/web patient programs SHARE web series Online videos Free booklets Patient Community Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by Merck & Co., Inc. The post The Bloodline Live!: Redefining Resilience first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with W. Kimryn Rathmell, MD, PhD, about the new and evolving ways cancer care is delivered, building networks through advocacy and more. ·       Who is Dr. W. Kimryn Rathmell?  2:17 ·       Jain and Rathmell discuss the need for physician scientists in administrative leadership. 11:37 ·       How do you think networks and communities can impact careers? 17:08 ·       What are your thoughts on using social media in the cancer space? 22:35 ·       How do you think AI is going to transform the way we deliver care? 26:21 ·       As you have navigated your career, how have you approached challenges around being a woman in leadership roles? 29:29 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Rathmell can be reached on LinkedIn. Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

──────────────────────────────────────── [00:04:09] Operation Warp Speed Killed More Americans Than Any Other War — Trump Calls Himself the Father of the Vaccine VAERS shows COVID shots produced more deaths and injuries than all other FDA-approved vaccines combined. Trump forced FDA approval and still boasts. Johnson blames Biden's FDA, not Trump. ──────────────────────────────────────── [00:15:25] Ron Johnson: Biggest Government Scandal of My Lifetime — FDA Knew It Was Hiding the Safety Signals FDA's vaccine division head was briefed their algorithm would mask signals — 26 days later hiding 60 signals including sudden cardiac death and stroke types. Johnson refuses to name Trump. ──────────────────────────────────────── [00:24:39] Trump's EPA Reversed the Fluoride Ruling by Banning All Scientific Evidence Produced After 2020 The Ninth Circuit sent the case back with instructions to exclude all evidence from the last six years. Lee Zeldin is also pushing to keep PFAS forever chemicals in the water. ──────────────────────────────────────── [00:32:57] Merck Is Lobbying to Give HPV Vaccines to Infants — Sales Are Down 40% Globally HPV is sexually transmitted — a four-year-old cannot be exposed to it. Merck hired former Gates Foundation advisors who declared no conflicts of interest. Childhood vaccine classification means zero liability. ──────────────────────────────────────── [00:43:48] Josh Shapiro: Tracking AIPAC's Money Is Racist — They Can Buy Congress, You Are Not Allowed to Watch Pennsylvania's governor said AIPAC tracking is intimidation. Knight: they're calling for speech to be criminalized. AIPAC doesn't register as a foreign agent — you can't look at who they're buying. ──────────────────────────────────────── [00:51:48] Todd Blanche's Background: Fake Mossad Agent, Twin Grifters, Forgery and Malpractice Accusations Before representing Trump, Blanche's clients used a fake Mossad agent to threaten witnesses and bribe DOJ officials. The case ended with forgery and malpractice accusations against Blanche. ──────────────────────────────────────── [01:15:23] Blanche Is Setting Up the Ghislaine Maxwell Pardon — After a Long Interview, She Was Moved to Club Fed Blanche visited Maxwell for a long interview; shortly after she was moved to comfortable quarters. He pushed prosecution of political enemies and declined to investigate those tight with Epstein. ──────────────────────────────────────── [01:21:24] The Trump Phone Is Finally Shipping — It's an HTC Running on American Values, Assembled in a Box After months of broken promises and removing buyer protections, Trump Mobile is shipping. CNET found the processor identical to a Taiwanese HTC. Designed with American values in mind. ──────────────────────────────────────── [01:41:44] SWAT Team Destroyed a Texas Woman's Home — Government Said She Wasn't a Victim — Six Years Later She May Get $60,000 Police were given the key, garage opener, and gate code — drove a Bearcat through the fence, blew up the garage, drove through the front door. Government argued she wasn't a victim. ──────────────────────────────────────── [01:50:06] Texas Woman Arrested Under a Bomb Threat Law for Posting That Her Town's Water Was Brown The police chief applied a felony false alarm statute — designed for fake bomb threats — to a woman warning neighbors about brown water. The city later admitted the water was undrinkable. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

What started as a revolutionary treatment for river blindness became something far messier. Listen to Drug Story wherever you get your podcasts! Subscribe to SiriusXM Podcasts+ to listen to new episodes of 99% Invisible ad-free and a whole week early. Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero,UCSF Cancer Early Detection and Interception, to discuss whether these tests are truly ready for clinical prime time.Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMEShow Segments 00:00 Introduction  01:57 Current Cancer Screening Programs  06:05 Emerging Blood-Based Cancer Tests  11:55 Test Characteristics and Limitations  18:05 Practical Considerations for Patients  25:33 Direct-to-Consumer Testing/Whole Body MRIs 36:46 Navigating Positive Test Results  45:10 Anxiety and Patient Education  47:08 Future Directions in Cancer Screening  Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Margaret Tempero, MD DisclosuresDr. Tempero reports the following financial relationships: Grail (research support), Global Bio Access Fund (Advisor), Bristol Myers Squibb (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Astra Zeneca (Membership on Advisory Committees or Review Panels, Board Membership, etc), Immunovia (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Merck (advisory committee), Renovo Rx (advisory committee), Urogen (Advisor). Financial relationships have not ended. The Curbsiders report no relevant financial disclosures. Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.  Sponsor: FreedTry Freed Front Desk free for 7 days at getfreed.ai/front-desk.Sponsor: Quince Go to Quince.com/curb for free shipping on your order  and 365-day returns. Now available in Canada, too.